Angelino Yson, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1336193465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 927 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 927 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amarin Pharma, Inc.$925
- Amgen$918
- Boehringer Ingelheim$910
- Sanofi-aventis U.S. LLC$786
- plus $8K from 54 others
What the payments were for
- Food & beverage$14,862100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,879 in reported general payments places this provider in the 80th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 320 | $559,088 |
| JardianceEmpagliflozin | 212 | $296,574 |
| TrulicityDulaglutide | 100 | $220,645 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $214,953 |
| Tresiba Flextouch U-100Insulin Degludec | 244 | $171,060 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $126,647 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $86,336 |
| TradjentaLinagliptin | 68 | $80,655 |
| MounjaroTirzepatide | 58 | $76,562 |
| FarxigaDapagliflozin Propanediol | 48 | $67,488 |
| VascepaIcosapent Ethyl | 71 | $59,912 |
| JanuviaSitagliptin Phosphate | 41 | $59,387 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $46,556 |
| Humalog Kwikpen U-100Insulin Lispro | 87 | $44,158 |
| Novolog FlexpenInsulin Aspart | 109 | $41,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $2,183 | $564,567331 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $910 | $393,137299 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,007 | $304,485174 claims |
| MerckJanuvia, Janumet Xr, Janumet | $251 | $116,215104 claims |
| AstraZenecaFarxiga | $693 | $67,48848 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $786 | $31,59326 claims |
| AbbVieSynthroid | $440 | $20,105283 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $309 | $6,660581 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Mehdi PoorkayLouisville$81K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
- Swapna DeoLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.